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161Tb (30 MBq/nmol) and investigated in vitro using 
somatostatin receptor-positive AR42J rat tumor cells. 
Viability and survival assays were performed in vitro. 
Results: In vivo application of 161Tb-folate (10 MBq) resulted 
in a reduced KB tumor growth and, as a consequence, in an 
increased survival time (54 d) of mice compared to those 
treated with 177Lu-folate (10 MBq, 35 d) [3]. Based on BUN 
and creatinine plasma values and histological investigations 
of renal tissues, 161Tb-folate did not result in more severe 
damage to the kidneys than 177Lu-folate, however. In vitro 
investigations with 161Tb-DOTATOC and 161Tb-DOTATOC-NLS 
revealed comparable uptake into AR42J cells, but 
externalization of 161Tb-DOTATOC-NLS was lower (~25%) than 
for 161Tb-DOTATOC (~55%) after 6 h. After 2 h of incubation 
the fraction of internalized 161Tb-DOTATOC-NLS, which was 
localized in the nucleus (~3%), was significantly higher than 
the fraction of 161Tb-DOTATOC (<0.5%). AR42J cell killing 
after application of 161Tb-DOTATOC-NLS was more effective 
(IC50 ~1.5 MBq/mL) than after treatment with 161Tb-
DOTATOC (IC50 ~8 MBq/mL). 
Conclusion: Due to additional Auger electron emission, 161Tb 
appears to be more effective for tumor treatment than 177Lu. 
The effect caused by Auger electrons was found to be more 
powerful if the radioconjugate targets the cellular nucleus by 
means of a NLS. Interestingly, kidney damage was not 
enhanced after therapy with 161Tb compared to the 
treatment with 177Lu. Based on these findings, 161Tb has a 
great potential to be used in future clinical practice as it may 
kill single cancer cells and cell clusters more efficiently than 
177Lu without causing additional side effects. 
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A triple GEM detector with a 55 μm pitch pixelated ASIC for 
the readout has been used at CNAO in Pavia for a detailed 
measurements of energy deposition inside a water phantom. 
The detector was operated with a gas mixture of Ar CO2 CF4 
at a moderate gain and the measurements were performed 
with a beam of 120 MeV protons and 330 MeV/u Carbon ions. 
The energy deposition was measured at different positions in 
depth allowing a 3D reconstruction of the beam inside the 
phantom as shown in the figure. A small number of single 
event upsets in the pixel readout appear only in the Bragg 
peak and the DAQ can recover them for each acquisition. A 
detailed simulation was performed with GEANT4 and it was 
found in good agreement with the experimental data. 
The future uses and upgrade of this device, including its 
potential application in microdosimetry, are discussed. 
 
 
 
 
Keywords: GEM Detector, Timepix readout, Hadrontherapy 
 
References:  
[1] F.Murtas, Applications of triple GEM detectors beyond 
particle and nuclear physics, 2014 JINST 9 C01058 
[2] S. P. George et al., Particle Tracking with a Timepix 
Based Triple GEM Detector, 2015 JINST_024P_0615 
[3] P. Piersimoni et al., Optimization of a general-purpose, 
actively scanned proton beamline for ocular treatments: 
Geant4 simulations, Journal of applied clinical medical 
physics, volume 16, number 2, 2015 
 
159 
OPEN-MED: LEIR Based biomedical infrastructure @ CERN 
M. Baumann1,2,3,4, P. Lambin5, S. Myers6, G. Roy6, M. 
Waligorski7,8 
1 OncoRay – National Center for Radiation Research in 
Oncology, Faculty of Medicine and University Hospital Carl 
Gustav Carus, Technische Universität Dresden, Helmholtz-
Zentrum Dresden – Rossendorf, Dresden, Germany 
2 Department of Radiation Oncology, Faculty of Medicine and 
University Hospital Carl Gustav Carus, Technische Universität 
Dresden, Dresden, Germany 
3 Helmholtz-Zentrum Dresden - Rossendorf, Institute of 
Radiooncology, Dresden, Germany 
4 German Cancer Consortium (DKTK), Dresden and German 
Cancer Research Center (DKFZ), Heidelberg, Germany 
5 Maastro Clinic, Maastricht, The Netherlands 
6 CERN 
7 Institute of Nuclear Physics PAN, Radzikowskiego 152, 31-
342 Krakow Poland 
8 Centre of Oncology (COOK), Garncarska 11, 31-115 Krakow 
Poland 
 
The need for an open-access biomedical research facility was 
first raised by the scientific community at the 2010 Physics 
for Health workshop, where CERN was asked to take the lead 
on this initiative.  
In 2012, a brainstorming meeting evaluated the possibility of 
modifying the existing CERN Low Energy Ion Ring (LEIR) 
accelerator to establish such an infrastructure.  The medical 
and radiobiological communities united in broad agreement 
on the need for such a dedicated research facility. 
The Biomedical facility at CERN (OPEN-MED) would create an 
open collaborative biomedical research infrastructure. By 
sharing the facility internationally, more rapid progress can 
be made by: 
• Complementary collaboration with leading 
universities, research facilities and industry  
• Comprehensively investigate complex physical and 
biological parameters that control radiation cell 
killing efficiency under highly controlled 
conditions.  
• Provide accurate data for the modelling of 
radiation effects for proton and ion beam clinical 
applications 
• Study comparative beam ballistics and dosimetry in 
phantoms and so improve predicted physical dose 
distributions.    
• Provide a range of beams and infrastructure for 
developing new instrumentation for detection and 
imaging. 
• Provide adequate beam time  
